Earnings Summary

Celldex Therapeutics, Inc.’s revenue jumped 64.42% since last year same period to $0.27Mn in the Q2 2023. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -72.29% fall in its revenue since last 3-months.

Celldex Therapeutics, Inc.’s net profit jumped 15.28% since last year same period to $-30.5Mn in the Q2 2023. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -3.89% fall in its net profits since last 3-months.

Celldex Therapeutics, Inc.’s net profit margin jumped 48.47% since last year same period to -11381.34% in the Q2 2023. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -274.84% fall in its net profit margins since last 3-months.

Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.59 - a -1.72% fall from last quarter’s estimates.

Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.59.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Celldex Therapeutics, Inc.’s return on assets (ROA) stands at -0.22.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Celldex Therapeutics, Inc.’s return on equity (ROE) stands at -0.35.